Comprehensive Stock Comparison
Compare Celldex Therapeutics, Inc. (CLDX) vs Regeneron Pharmaceuticals, Inc. (REGN) vs Centessa Pharmaceuticals plc (CNTA) vs Immunome, Inc. (IMNM) vs Recursion Pharmaceuticals, Inc. (RXRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | RXRX | 26.9% revenue growth vs CNTA's -100.0% |
| Quality / Margins | REGN | 31.4% net margin vs CLDX's -172.5% |
| Stability / Safety | REGN | Beta 0.58 vs RXRX's 2.38 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; CLDX, CNTA, IMNM, RXRX pay no meaningful dividend |
| Momentum (1Y) | IMNM | +132.6% vs RXRX's -51.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs IMNM's -74.4%, ROIC 12.4% vs -7.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for cancer and inflammatory diseases. It generates revenue primarily through research collaborations and licensing agreements — with future income dependent on successful clinical development and commercialization of its pipeline candidates. The company's competitive advantage lies in its proprietary antibody platform technology and focused expertise in developing monoclonal and bispecific antibodies against validated targets.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel medicines for serious diseases. It generates revenue primarily through research collaborations and licensing agreements — though as a pre-commercial company, it currently relies on equity financing and partnerships to fund development. The company's competitive advantage lies in its asset-centric model — each program operates as an independent "company" with dedicated resources and accountability — and its LockBody platform technology designed to create targeted cancer therapies with reduced systemic toxicity.
Immunome is a biopharmaceutical company that discovers and develops antibody therapeutics for cancer and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — as it advances its pipeline of antibody candidates. The company's key advantage lies in its proprietary discovery platform that identifies human antibodies from patient immune responses, potentially yielding more effective and safer therapeutic candidates.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses an industrialized, technology-driven platform to discover and develop new drugs. It generates revenue primarily through research collaborations and partnerships with pharmaceutical companies — like its major deal with Bayer — while advancing its own pipeline of drug candidates. Its key competitive advantage is its proprietary platform that combines automation, artificial intelligence, and massive biological datasets to systematically decode biology and accelerate drug discovery at scale.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
REGN leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). CNTA leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 9561.9x CLDX's $2M. REGN is the more profitable business, keeping 31.4% of every revenue dollar as net income compared to CLDX's -172.5%. On growth, RXRX holds the edge at +6.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CLDXCelldex Therapeut… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $14.3B | $15M | $10M | $75M |
| EBITDAEarnings before interest/tax | -$284M | $4.2B | -$213M | -$232M | -$564M |
| Net IncomeAfter-tax profit | -$259M | $4.5B | -$243M | -$223M | -$645M |
| Free Cash FlowCash after capex | -$213M | $3.2B | -$181M | -$192M | -$378M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +86.3% | +100.0% | -4.2% | -32.1% |
| Operating MarginEBIT ÷ Revenue | -191.6% | +25.7% | -14.3% | -24.2% | -8.7% |
| Net MarginNet income ÷ Revenue | -172.5% | +31.4% | -16.2% | -23.0% | -8.6% |
| FCF MarginFCF ÷ Revenue | -142.2% | +22.0% | -12.1% | -19.8% | -5.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -93.6% | +2.5% | — | -100.0% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -73.2% | -2.5% | -10.8% | +16.7% | +60.4% |
Valuation Metrics
| Metric | CLDXCelldex Therapeut… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|---|---|---|
| Market CapShares × price | $2.0B | $107.6B | $3.6B | $2.0B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $2.0B | $91.4B | $3.3B | $1.9B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -7.72x | 18.84x | -13.04x | -4.37x | -2.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.25x | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | 2.98x | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 21.64x | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 1334.98x | 7.50x | — | 221.74x | 25.96x |
| Price / BookPrice ÷ Book value/share | 3.80x | 2.72x | 7.66x | 7.08x | 1.45x |
| Price / FCFMarket cap ÷ FCF | — | 26.36x | — | — | — |
Profitability & Efficiency
REGN delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-84 for IMNM. CLDX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNTA's 0.29x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs IMNM's 1/9, reflecting strong financial health.
| Metric | CLDXCelldex Therapeut… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -49.1% | +14.4% | -80.5% | -84.4% | -57.0% |
| ROA (TTM)Return on assets | -44.4% | +11.1% | -54.1% | -74.4% | -43.7% |
| ROICReturn on invested capital | -35.2% | +12.4% | -91.8% | -7.0% | -95.8% |
| ROCEReturn on capital employed | -44.7% | +10.8% | -47.9% | -195.6% | -50.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 3 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.09x | 0.29x | 0.03x | 0.07x |
| Net DebtTotal debt minus cash | -$27M | -$16.2B | -$266M | -$139M | -$665M |
| Cash & Equiv.Liquid assets | $29M | $18.9B | $383M | $143M | $743M |
| Total DebtShort + long-term debt | $2M | $2.7B | $117M | $5M | $78M |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x | -20.50x | — | -491.16x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $16,977 today (with dividends reinvested), compared to $2,039 for RXRX. Over the past 12 months, IMNM leads with a +132.6% total return vs RXRX's -51.1%. The 3-year compound annual growth rate (CAGR) favors CNTA at 96.9% vs RXRX's -23.4% — a key indicator of consistent wealth creation.
| Metric | CLDXCelldex Therapeut… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +11.4% | +0.8% | +13.4% | +5.0% | -12.6% |
| 1-Year ReturnPast 12 months | +46.3% | +12.4% | +72.7% | +132.6% | -51.1% |
| 3-Year ReturnCumulative with dividends | -29.7% | +3.4% | +663.1% | +378.3% | -55.0% |
| 5-Year ReturnCumulative with dividends | +6.7% | +69.8% | +23.5% | -45.3% | -79.6% |
| 10-Year ReturnCumulative with dividends | -70.5% | +104.7% | +23.5% | +62.5% | -79.6% |
| CAGR (3Y)Annualised 3-year return | -11.1% | +1.1% | +96.9% | +68.5% | -23.4% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than RXRX's 2.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLDX currently trades 96.2% from its 52-week high vs RXRX's 46.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CLDXCelldex Therapeut… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 0.58x | 0.98x | 1.42x | 2.38x |
| 52-Week HighHighest price in past year | $31.29 | $821.11 | $30.58 | $27.65 | $7.89 |
| 52-Week LowLowest price in past year | $14.40 | $476.49 | $9.60 | $5.15 | $2.98 |
| % of 52W HighCurrent price vs 52-week peak | +96.2% | +95.2% | +87.8% | +79.1% | +46.5% |
| RSI (14)Momentum oscillator 0–100 | 71.7 | 49.1 | 65.7 | 42.9 | 46.7 |
| Avg Volume (50D)Average daily shares traded | 547K | 687K | 1.2M | 1.5M | 18.2M |
Analyst Outlook
Analyst consensus: CLDX as "Buy", REGN as "Buy", CNTA as "Buy", IMNM as "Buy", RXRX as "Hold". Consensus price targets imply 199.7% upside for RXRX (target: $11) vs -20.2% for CLDX (target: $24). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | CLDXCelldex Therapeut… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $24.00 | $857.17 | $37.33 | $35.29 | $11.00 |
| # AnalystsCovering analysts | 19 | 48 | 11 | 9 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | $3.41 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% | 0.0% | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 21 | Feb 26 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | 100 | 88.77 | -11.2% |
| Regeneron Pharmaceu… (REGN) | 100 | 150.03 | +50.0% |
| Centessa Pharmaceut… (CNTA) | 108.41 | 115.82 | +6.8% |
| Immunome, Inc. (IMNM) | 100 | 127.02 | +27.0% |
| Recursion Pharmaceu… (RXRX) | 100 | 14.68 | -85.3% |
Regeneron Pharmaceu… (REGN) returned +70% over 5 years vs Recursion Pharmaceu… (RXRX)'s -80%. A $10,000 investment in REGN 5 years ago would be worth $16,977 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | $7M | $2M | -77.9% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
| Centessa Pharmaceut… (CNTA) | $0.00 | $0.00 | — |
| Immunome, Inc. (IMNM) | $0.00 | $9M | — |
| Recursion Pharmaceu… (RXRX) | $2M | $75M | +4264.8% |
Celldex Therapeutics, Inc.'s revenue grew from $7M (2016) to $2M (2025) — a -15.4% CAGR. Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | -18.9% | -172.5% | -810.9% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
| Centessa Pharmaceut… (CNTA) | -22.0% | -22.0% | +0.0% |
| Immunome, Inc. (IMNM) | -7.6% | -32.4% | -325.3% |
| Recursion Pharmaceu… (RXRX) | -36.5% | -8.6% | +76.4% |
Celldex Therapeutics, Inc.'s net margin went from -19% (2016) to -173% (2025). Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | -18.99 | -3.9 | +79.5% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
| Centessa Pharmaceut… (CNTA) | -0.08 | -2.06 | -2551.2% |
| Immunome, Inc. (IMNM) | -7.18 | -5 | +30.4% |
| Recursion Pharmaceu… (RXRX) | -0.37 | -1.44 | -285.9% |
Celldex Therapeutics, Inc.'s EPS grew from $-18.99 (2016) to $-3.90 (2025). Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
Celldex Therapeutics, Inc. generated $-211M FCF in 2025 (-239% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
CLDX vs REGN vs CNTA vs IMNM vs RXRX: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is CLDX or REGN or CNTA or IMNM or RXRX a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 18.8x trailing P/E (17.3x forward), making it the more compelling value choice. Analysts rate Celldex Therapeutics, Inc. (CLDX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CLDX or REGN or CNTA or IMNM or RXRX?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to -79.6% for Recursion Pharmaceuticals, Inc. (RXRX). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +104.7% versus RXRX's -79.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CLDX or REGN or CNTA or IMNM or RXRX?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus Recursion Pharmaceuticals, Inc.'s 2.38β — meaning RXRX is approximately 313% more volatile than REGN relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 29% for Centessa Pharmaceuticals plc — giving it more financial flexibility in a downturn.
04Which has better profit margins — CLDX or REGN or CNTA or IMNM or RXRX?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus -172.5% for Celldex Therapeutics, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus -191.6% for CLDX. At the gross margin level — before operating expenses — CLDX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is CLDX or REGN or CNTA or IMNM or RXRX more undervalued right now?
Analyst consensus price targets imply the most upside for RXRX: 199.7% to $11.00.
06Which pays a better dividend — CLDX or REGN or CNTA or IMNM or RXRX?
In this comparison, REGN (0.4% yield) pays a dividend. CLDX, CNTA, IMNM, RXRX do not pay a meaningful dividend and should not be held primarily for income.
07Is CLDX or REGN or CNTA or IMNM or RXRX better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58), +104.7% 10Y return). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2.38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +104.7%, RXRX: -79.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CLDX and REGN and CNTA and IMNM and RXRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.